Predicting survival in malignant mesothelioma

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1420-1424

  Musk, A W ^a,d   Olsen, N ^a,c   Alfonso, H ^b   Reid, A ^a   Mina, R ^a   Franklin, P ^a   Sleith, J ^a   Hammond, N ^d   Threlfall, T ^c   Shilkin, K B ^a,e   De Klerk, N H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Western Australian Cancer Registry   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Mesothelioma; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; ONSET AGE; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEASONAL VARIATION; SEX RATIO; SURVIVAL RATE;

ADULT; AGED; ASBESTOS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; REGISTRIES; SEX FACTORS; SURVIVAL ANALYSIS; WESTERN AUSTRALIA; YOUNG ADULT;

EID: 82555194429     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00000811     Document Type: Article

References (33)

1. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
2. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60: 259-263.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
4. Rusch VW, Piantadosi S, Holmes EC, et al. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
5. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996; 224: 288-294.
6. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009; 4: 1010-1016.
7. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152.
8. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007; 2: 957-965.
9. Harvey JC, Fleischman EH, Kagan AR, et al. Malignant pleural mesothelioma: a survival study. J Surg Oncol 1990; 45: 40-42.
10. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
11. Huncharek M, Kelsey K, Mark EJ, et al. Treatment and survival in diffusemalignant pleuralmesothelioma; a study of 83 cases fromthe Massachusetts General Hospital. Anticancer Res 1996; 16: 1265-1268.
12. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008; 6: 293-297.
13. Viallat JR, Boutin C, Rey F, et al. [Malignant mesothelioma: study of prognostic factors in a series of 188 cases]. Arch Anat Cytol Pathol 1993; 41: 205-211.
14. Musk AW, Woodward SD. Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust NZ J Med 1982; 12: 229-232.
15. Chapman A, Mulrennan S, Ladd B, et al. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008; 63: 435-439.
16. Gorini G, De Gregorio G, Silvestri S, et al. Survival ofmalignantpleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988-2000: a population-based study. Eur J Cancer Prev 2005; 14: 195-199.
17. Magnani C, Viscomi S, Dalmasso P, et al. Survival after pleural malignant mesothelioma: a population-based study in Italy. Tumori 2002; 88: 266-269.
18. Marinaccio A, Nesti M. Analysis of survival of mesothelioma cases in the Italian register (ReNaM). Eur J Cancer 2003; 39: 1290-1295.
19. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009; 124: 201-207.
20. Neumann V, Rutten A, Scharmach M, et al. Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health 2004; 77: 191-199.
21. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41: 525-530.
22. Van Gelder T, Damhuis RA, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994; 7: 1035-1038.
23. Musk AW, de Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004; 45: Suppl. 1, S21-S23.
24. Musk AW, de Klerk NH, Eccles JL, et al. Wittenoom, Western Australia: a modern industrial disaster. Am J Ind Med 1992; 21: 735-747.
25. Musk AW, Dolin PJ, Armstrong BK, et al. The incidence of malignant mesothelioma in Australia, 1947-1980. Med J Aust 1989; 150, 242-243: 246.
26. Ferguson DA, Berry G, Jelihovsky T, et al. The Australian Mesothelioma Surveillance Program 1979-1985. Med J Aust 1987; 147: 166-172.
27. Alfonso HS, Reid A, de Klerk NH, et al. Retinol supplementation and mesothelioma incidence in workers earlier exposed to blue asbestos (Crocidolite) at Wittenoom, Western Australia. Eur J Cancer Prev, 19: 355-359.
28. De Klerk NH, Musk AW, Ambrosini GL, et al. Vitamin A and cancer prevention II: comparison of the effects of retinol and β-carotene. Int J Cancer 1998; 75: 362-367.
29. Musk AW, de Klerk NH, Ambrosini GL, et al. Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer 1998; 75: 355-361.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
31. Mirabelli D, Roberti S, Gangemi M, et al. Survival of peritoneal malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009; 124: 194-200.
32. Kanazawa N, Ioka A, Tsukuma H, et al. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 2006; 36: 254-257.
33. Safe Work Australia. Asbestos Exposure and Compliance Study of Construction and Maintenance Workers. Canberra, Commonwealth of Australia, 2009.